iinews – Der mobile Newsdienst

« | »

Research details developments in the Vaccines market worth USD 50.42 billion by 2023


According to new research report \“Vaccines Market by Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Technology (Live, Toxoid, Recombinant), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type – Global Forecast to 2023\“, the global market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%.

Market Dynamics


High prevalence of infectious diseases

High cost of vaccine development

High growth prospects in emerging markets

Inadequate access to vaccines
To know about the assumptions considered for the study, download the pdf brochure @: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1155

Major Key Players in This Report Include,

 GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), MedImmune, LLC (US), Astellas Pharma Inc. (Japan), Serum Institute of India, Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).

The following are the major objectives of the study:

To define, describe, and forecast the global market on the basis of technology, type, disease indication, route of administration, and patient type
To describe and forecast the market, in terms of value, by region–Asia, Europe, North America, and Rest of the World (RoW) along with their respective countries
To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets with respect to individual growth trends,
To speak to our analyst for a discussion on the above findings, click @: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1155

Major Developments

In 2016, Pfizer collaborated with Western Oncolytics to advance Western Oncolytics’ novel oncolytic vaccinia virus.
In 2016, GlaxoSmithKline collaborated with Vaccine Research Center at the NIH (US) to evaluate a new vaccine technology for Zika, known as SAM.
In 2017, Merck collaborated with Premier, Inc. (US) to develop a preventive care model that seeks to improve adolescent and adult vaccination rates.
Get Sample Report with all Graphs & Charts related to it @: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1155

Posted by on 18. April 2019.

Tags: , , , , , , , , , ,

Categories: Bilder, Vermischtes

0 Responses

You must be logged in to post a comment.

« | »

Neueste Beiträge